Boston Scientific continues to win in electrophysiology

Strong sales growth in the company’s electrophysiology unit comes amid a market fight between some of the medtech industry’s largest players.

Hologic to go private for up to $18.3B

Funds managed by Blackstone and TPG plan to acquire the medtech firm for up to $79 per share.

CoMind raises $102.5M to develop non-invasive bedside brain monitor

The company is enrolling patients in an early feasibility trial as part of plans to launch its device in 2027.

AHA urges tariff exceptions for certain PPE, medical devices

The American Hospital Association warned future tariffs arising from the Trump administration’s Section 232 investigation could disrupt access to an array of tools and personal protective equipment.

Biolinq’s Jared Tangney on making CGMs unintimidating

The chief technology officer and co-founder explained the technology and design choices that went into Biolinq’s device, which he hopes will be easier to use than other glucose monitors.

MDMA warns Section 232 tariffs could hurt US medtech manufacturing

The trade group said levies would “needlessly disrupt a globally integrated industry that already meets domestic demand.”

AdvaMed calls for series of trade actions in response to Section 232 probe

In comments submitted to the Trump administration on its medical equipment investigation, the industry group recommended a tariff-free trading bloc with trusted countries among its proposals.

Dexcom faces proposed class action suit over G7 CGM problems

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

HHS says it can still fire workers despite judge’s order pausing shutdown layoffs

The 982 HHS employees who received reduction-in-force notices are not represented by the unions that are plaintiffs in the case, the department’s head of personnel argued in a court filing.

Ōura to pursue FDA clearance of blood pressure feature for smart ring

The company has received approval to validate and define the feature in a study that is scheduled to start this year.

Boston Scientific to buy Nalu Medical for $533M

Nalu’s implantable neurostimulation system delivers electrical impulses to treat chronic pain originating from the peripheral nerves.

What J&J’s ortho spinoff means for the industry

Analysts expect that DePuy Synthes could become a stronger competitor as a standalone company.

Ōura raises $900M to develop new health features

The investment values the smart-ring maker at $11 billion.

HistoSonics raises $250M to expand use of noninvasive cancer therapy

The company raised money from Bezos Expeditions, Thiel Bio and other investors to fund the commercial and clinical expansion of its technology.

BD CFO Chris DelOrefice leaving for new job

Along with DelOrefice’s departure, BD reported preliminary fiscal fourth-quarter revenue that analysts said was below Wall Street consensus expectations.

5 AI takeaways from AdvaMed’s conference

Medical device firms discussed privacy, regulations and prioritizing projects as AI becomes more prevalent in the industry.

J&J plans to spin out orthopedics business

CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such as cardiovascular and robotics.

Abbott CEO: ‘We’re right on time’ to the PFA party

As competitors have launched their first pulsed field ablation devices in the U.S., Abbott CEO Robert Ford told investors that the company is not just playing defense.

To move or not to move? Manufacturers hesitant to nearshore before USMCA review

While some companies are using regional supply chains or leaning on tariff exemptions by maximizing compliance, others are frozen in place.

Stereotaxis teams with CardioFocus to develop robotic PFA system

Stereotaxis CEO David Fischel said the precision, stability and safety profile of robotics are a good fit for pulsed field ablation.

Cybersecurity triggers another recall of J&J’s Impella heart pump controller

While no patients have been harmed, the FDA categorized the action as a Class I recall because of the potential for serious injury or death.

Trump administration moves to fire HHS employees amid shutdown

Upwards of 1,000 HHS employees were affected. However, the department has rolled back some of the layoffs at the CDC, where the brunt of the terminations were concentrated.

Updated Oct. 14, 2025

Intuitive expands AI in Ion; Horizon performs first robotic cataract surgery

The FDA cleared AI and imaging updates for Intuitive’s lung biopsy robot. Elsewhere, Horizon completed the first cataract surgery with its robotic system, and MMI began a neurosurgical study.